Bayer and BridgeBio Collaborate to Commercialize Acoramidis for Treating Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Europe
Shots:
- Bayer & BridgeBio have collaborated under which Bayer gains exclusive license for the commercialization of acoramidis to treat ATTR-CM in the EU
- Under the collaboration, BridgeBio is entitled to receive ~$310M payment incl. upfront & near-term milestones, additional undisclosed sales-based milestones as well as low-thirties percent tiered royalties
- Moreover, the MAA for the drug was filed to the EMA in Jan 2024 with the approval anticipated in 2025 and the NDA for the same has been accepted by the US FDA, based on the P-III (ATTRibute-CM) study, with the decision expected on Nov 29, 2024
Ref: BridgeBio | Image: BridgeBio
Related News:- bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
